From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. Dermatology>
  4. Summary and Comment

Lash Failure

A glaucoma treatment can increase eyelash growth but not, unfortunately, in patients with alopecia areata–related eyelash loss.

Application of latanoprost to eyelashes increases their number, thickness, and darkness. Some patients with alopecia areata lose their eyelashes, and many physicians have hoped, reasonably, that the drug would induce eyelash and eyebrow growth in these patients. Faghihi and colleagues conducted a bilateral-paired comparison study to test the efficacy of latanoprost for restoring lashes and brows in 26 patients.

All 26 patients had had alopecia areata for at least 3 months, and all had lost more than 50% of the hair on their eyebrows and eyelashes. The patients were instructed to apply a drop of topical latanoprost 0.005% to one eyebrow and another drop to the upper and lower eyelashes of the ipsilateral eye. Lashes and brows on the other side of the face remained untreated. Four months later, the researchers compared patients' current status with photographs taken at study entrance. Changes from baseline were recorded in terms of global response to latanoprost, defined as absent (0%–25%), partial response (26%–75%), or complete response (76%–100%). All patients completed the study. Only one patient had any response, and that was a partial response on the drug-treated side.

Comment: This is at least the fourth study of latanoprost conducted in hopes of finding a successful treatment for the loss of eyelid and eyebrow hair in alopecia areata. As in the other three studies, latanoprost failed to induce meaningful regrowth for these patients.

Mark V. Dahl, MD

Published in Journal Watch Dermatology February 5, 2010

Citation(s):

Faghihi G et al. The efficacy of latanoprost in the treatment of alopecia areata of eyelashes and eyebrows. Eur J Dermatol 2009 Nov/Dec; 19:586.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

The editors of Journal Watch may respond to Reader Remarks, but we cannot promise to respond to a particular remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Sign-In

Forgot your password? Login via Athens
or your institution

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2010. Massachusetts Medical Society. All rights reserved.